Vivos Therapeutics, Inc. VVOS
At closeNov 4, 2026, 4:22 AM EST
Pre-market · Nov 4, 4:22 AM ET
- YTD
- -94.59%
- 1 year
- -95.55%
- Market cap
- 3.69M
- Revenue (ttm)
- 14.02M
- Profit margin
- -85.90%
- EPS (ttm)
- -1.93
- Shares out
- 4.84M
- Forward P/E
- -9.31
- YTD return
- -94.59%
- 1-year return
- -95.55%
- Volume
- 438.73K
- Avg volume
- 15.04M
- Open
- 0.1091
- Previous close
- 0.1083
- Day's range
- 0.1063 – 0.1124
- 52-week range
- 0.1063 – 2.72
- Beta
- 7.68
- Price target
- 6.30 (+5637.7%)
- Earnings date
- Aug 14, 2024
2Y -2.5787 (-95.86%)
Key statistics
- Enterprise value
- 4.52M
- PEG ratio
- 0.00
- Price / sales
- 1.77
- Price / book
- 22.86
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 19.40%
- Free cash flow
- -8.90M
- Total cash
- 6.90M
- Total debt
- 1.76M
- Return on equity
- -284.96%
- Short % of float
- 2.01%
- 50-day average
- 3.32
- 200-day average
- 2.88
Analyst view
- Target (low)
- 6.00
- Target (mean)
- 6.30
- Target (high)
- 6.60
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.43.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.70 | -0.40 | +0.30 | +42.86% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.60 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | -1.63 | — | — |
| May 14, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | -3.05 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 20, 2024 | Ascendiant Capital | reit | Buy | Buy |
| Nov 19, 2024 | Alliance Global Partners | main | Buy | Buy |
| Aug 20, 2024 | Ascendiant Capital | main | Buy | Buy |
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- vivos.com
News
Why 3M Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket 
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M 
12 Health Care Stocks Moving In Monday's After-Market Session 
Vivos Therapeutics To Acquire 11% Stake In SOD Sciences And A 50% Interest In SOD’s Proprietary Pseudohypoxia Early-Warning Test For 12K Shares Of Newly Created Convertible Prefs Worth $12M
Your note
Sign in to keep a note on VVOS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| HUNTSMAN RONALD KIRK | Chief Executive Officer | Purchase | Jun 19, 2023 | 1,826,520 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Strategic Wealth Investment Group, LLC | 2.07% | 100,000 | 512.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.60% | 28,802 | 147.47K | Sep 29, 2024 |
| OMERS Administration Corporation | 0.52% | 25,000 | 128.00K | Sep 29, 2024 |
| Commonwealth Equity Services, LLC | 0.43% | 21,000 | 107.52K | Sep 29, 2024 |
| Sabby Management, LLC | 0.42% | 20,502 | 104.97K | Sep 29, 2024 |
| Two Sigma Investments, LP | 0.42% | 20,482 | 104.87K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.38% | 18,247 | 93.42K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.22% | 10,579 | 54.16K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.12% | 5,825 | 29.82K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.12% | 5,667 | 29.02K | Oct 30, 2024 |